45.18 -0.38 (-0.83%) | 02-12 19:24 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 54.44 | 1-year : | 63.58 |
Resists | First : | 46.61 | Second : | 54.44 |
Pivot price | 37.85 ![]() |
|||
Supports | First : | 35.23 | Second : | 28.2 |
MAs | MA(5) : | 44.99 ![]() |
MA(20) : | 37.11 ![]() |
MA(100) : | 33.52 ![]() |
MA(250) : | 14.13 ![]() |
|
MACD | MACD : | 2.1 ![]() |
Signal : | 0.7 ![]() |
%K %D | K(14,3) : | 94.9 ![]() |
D(3) : | 96.2 ![]() |
RSI | RSI(14): 67.2 ![]() |
|||
52-week | High : | 79.01 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DRUG ] has closed below upper band by 19.1%. Bollinger Bands are 23.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 46.2 - 46.48 | 46.48 - 46.69 |
Low: | 39.49 - 39.81 | 39.81 - 40.04 |
Close: | 44.71 - 45.23 | 45.23 - 45.6 |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Thu, 23 Jan 2025
Piper Sandler sets $93 target for Bright Minds Biosciences stock - Investing.com
Tue, 31 Dec 2024
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
Mon, 04 Nov 2024
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - Yahoo Finance
Fri, 18 Oct 2024
Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days - Mugglehead
Fri, 18 Oct 2024
Bright Minds stock gains post-private placement (DRUG:NASDAQ) - Seeking Alpha
Wed, 16 Oct 2024
Companies Like Bright Minds Biosciences (CSE:DRUG) Can Afford To Invest In Growth - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 7 (M) |
Shares Float | 1 (M) |
Held by Insiders | 27.2 (%) |
Held by Institutions | 44.2 (%) |
Shares Short | 221 (K) |
Shares Short P.Month | 265 (K) |
EPS | -0.45 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.37 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -28.9 % |
Return on Equity (ttm) | -51.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -3 (M) |
Levered Free Cash Flow | -1 (M) |
PE Ratio | -100.41 |
PEG Ratio | 0 |
Price to Book value | 32.97 |
Price to Sales | 0 |
Price to Cash Flow | -122.41 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |